[{"id":"fabc02d4-5366-472b-86ce-cd6cd0d86bc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02903771","created_at":"2021-01-18T14:15:02.327Z","updated_at":"2024-07-02T16:36:45.850Z","phase":"Phase 1","brief_title":"Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.","source_id_and_acronym":"NCT02903771","lead_sponsor":"Kazia Therapeutics Limited","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cantrixil (TRX-E-002-1)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 03/24/2020","primary_completion_date":" 03/24/2020","study_txt":" Completion: 03/24/2020","study_completion_date":" 03/24/2020","last_update_posted":"2020-04-20"}]